Italia markets close in 7 hours 49 minutes

AstraZeneca PLC (AZN)

NasdaqGS - NasdaqGS Prezzo in tempo reale. Valuta in USD.
Aggiungi a portafoglio
53,25+0,70 (+1,33%)
Alla chiusura: 4:00PM EST

AstraZeneca PLC

1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom
44 20 3749 5000
http://www.astrazeneca.com

Settore/iHealthcare
SettoreDrug Manufacturers—General
Impiegati a tempo pieno70.600

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Pascal Soriot D.V.M., M.B.A.CEO & Exec. DirectorN/DN/D1959
Mr. Marc DunoyerCFO & Exec. DirectorN/DN/D1952
Ms. Pam P. ChengExec. Vice-Pres of Operations & Information TechnologyN/DN/D1971
Thomas Kudsk LarsenHead of Investor RelationsN/DN/DN/D
Mr. Jefrey PottExec. VP of HR & Gen. CounselN/DN/DN/D
Ms. Katarina AgeborgExec. VP of Sustainability & Chief Compliance OfficerN/DN/DN/D
Dr. Menelas PangalosExec. Vice-Pres of BioPharmaceuticals R&DN/DN/DN/D
Dr. Ruud DobberExec. Vice-Pres of BioPharmaceuticals Bus. UnitN/DN/DN/D
Dr. Susan Mary GalbraithSr. VP and Head of Research, Early Devel. & Oncology R&DN/DN/D1966
Dr. David B. Goldstein Ph.D.Chief AdviserN/DN/DN/D
Gli importi risalgono al giorno e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR/Komboglyze, Onglyza, Qtern, Symlin, Xigduo/Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Tudorza/Eklira, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalen and Synagis for infection diseases; Movantik/Moventig, Seroquel IR/Seroquel XR, and Vimovo for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Arcus Biosciences, Inc. to evaluate domvanalimab (AB154), an investigational anti-TIGIT antibody in combination with Imfinzi (durvalumab); Fusion Pharmaceuticals Inc. to develop and commercialize next-generation alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer; and Recombinetics Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.

Governance aziendale

L'ISS Governance QualityScore di AstraZeneca PLC al 22 gennaio 2021 è 7. I criteri di valutazione fondamentali sono revisione: 1; Consiglio di Amministrazione: 6; diritti degli azionisti: 10; retribuzione: 4.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.